Alberta Health Services is reaching out to 49 Calgarians who attended the South Calgary Health Centre for vaccinations on March 23 and March 25 as they may have been exposed to a staff member who has since tested positive.
Officials say the risk of exposure is small due to PPE being worn and safety protocols being in place.
“The healthcare worker worked at the site from 8 a.m. to 12:15 p.m. on March 23 and from 8 a.m. to 4:15 p.m. on March 25,” AHS said in a statement.
“AHS is reaching out to the individuals directly and only those who are contacted by Health Link require testing.”
As of Tuesday afternoon, Chief Medical Officer of Health Dr. Deena Hinshaw said more than 620,000 doses of vaccine have been delivered in Alberta.
The province announced 576 new cases on Tuesday and there are 301 people in hospital, including 58 in ICU.
The province has said all Albertans who want the vaccine will be able to get a first dose by the end of June.
Also on Monday, the province announced it is halting the use of the AstraZeneca vaccine for those under age 55.
COVID cases in Ontario could spike to 30,000 per day by June
TORONTO (Reuters) – New cases of COVID-19 in Canada‘s most populous province could rise more than six fold, topping 30,000 per day by early June if public health measures are weak and vaccination rates remain flat, a panel of experts advising the province of Ontario said on Friday.
Even if measures to control the virus are “moderate,” the number of patients in Ontario ICUs could reach 2,000 in May, up from 695 on Friday.
The College of Physicians and Surgeons of Ontario told doctors last week they may soon have to decide who can and cannot receive intensive care.
(Reporting by Allison Martell; Editing by Chris Reese)
Moderna sees shortfall in Britain COVID vaccine shipments, EU deliveries on track
ZURICH (Reuters) – U.S. drugmaker Moderna expects a shortfall in COVID-19 vaccine doses from its European supply chain hitting second-quarter delivery quantities for Britain and Canada, though European Union– and Swiss-bound shipments are on track, a spokesperson said.
The delays, first announced on Friday when Canada said Moderna would be delivering only about half the planned 1.2 million doses by the end of April, come as Switzerland’s Lonza ramps up three new production lines to make active ingredients for Moderna vaccine supplies outside of the United States.
“The trajectory of vaccine manufacturing ramp-up is not linear, and despite best efforts, there is a shortfall in previously estimated doses from the European supply chain,” Moderna said in a statement.
Lonza didn’t immediately return a phone call and email seeking comment on any issues in its production.
(Reporting by John Miller; editing by David Evans)
Moderna says vaccines to Canada to be delayed due to Europe shortfall
(Reuters) -Moderna Inc said on Friday a shortfall in COVID-19 vaccine doses from its European supply chain will lead to a delay in deliveries to some countries including Canada.
She said one to two million doses of the 12.3 million doses scheduled for delivery by Moderna in the second quarter would be delayed until the third.
Moderna officials in Europe did not immediately comment on the reason for the delays or give the total number of countries that would be impacted.
“Vaccine manufacturing is a highly complex process and a number of elements, including human and material resources have factored into this volatility,” said Patricia Gauthier, an executive at Moderna Canada.
Canada has distributed a total of 2.82 million doses of the Moderna vaccine as of April 14 and 12.7 million doses of COVID-19 vaccines in total.
Moderna has been aiming to deliver 700 million to 1 billion doses of the COVID-19 globally this year, including from plants in Europe and the United States.
Swiss contract drug manufacturer Lonza makes active ingredients for Moderna’s vaccine in Visp, but it was still ramping up three new production lines that once operational would be able to produce 300 million shots annually.
The current supply, demand and distribution landscape has led the drugmaker to make adjustments in the expected second-quarter deliveries, Gauthier said.
(Reporting by Manas Mishra in Bengaluru, Allison Martell in Toronto and John Miller in Zurich; Editing by Arun Koyyur)